Why Is Everyone Talking About CureVac Stock?

Why Is Everyone Talking About CureVac Stock?

On June 17, shares of CureVac (NASDAQ: CVAC) plunged by over 50% during the trading session after the company announced its mRNA coronavirus vaccine candidate CVnCoV had achieved just 47% overall efficacy in preventing COVID-19 during the second interim analysis of a pivotal phase 3 study. Suspicions about the vaccine candidate's potential had already been spreading after it passed the first interim analysis without disclosure of efficacy rates. Just what are the odds that CureVac stock can recoup its losses?